Dr Reddy's adds PEG and API capacity at UK site

Dr Reddy's expands UK services business

Related tags Generic drug

Dr Reddy's Laboratories has added conjugation tech production capacity its UK plant.

The Indian drugmaker unveiled the new capacity at its facility in Mirfield, England this week, explaining that the enable it produce 'metric tonne scale quantities' of its PEGtech - methyl ether polyethylene glycol (mPEG) - range of conjugation technologies.

Dr Reddy's claims its PEGtech business is used by a wide range of developers - from biotechs to large biopharmas - seeking to "improve the stability and the pharmaco-kinetic properties of biologic drugs.​"

Early R&D services are provided at its subsidiary Chirotech - also located in the UK at a site in Cambridge - and the expansion establishes Mirfield as the scale-up ad commercial production facility.

R. Ananthanarayanan, president of the Indian firm's pharma services business, made reference to the firm's efforts to grow in the UK.

This expansion builds on our commitment to expand operations in UK and provide a superior network of cGMP manufacturing to support our global customer base. PEGylation is one area where we felt the need for expanding our capabilities​."

API expansion

Dr Reddy's has also added active pharmaceutical ingredient (API) production capacity at Mirfield for batch sizes for preclinical development, scale-up and commercial production.

The investment means the Indian generic drugmaker now has eight API fully operational production plants after the US FDA lifted an import ban it imposed in the firm's facility in Mexico in July​.

At the time Dr Reddy's said: "With the satisfactory closure of observations in the warning Letter and the lifting of the import alert, Dr. Reddy's can now start importing products to the US from this facility.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more